Top Markets
Coin of the day
Valbiotis SA Valbiotis SA

Valbiotis SA

ALVAL
株式のランク #16315
Valbiotis SA engages in the research and development of health nutrition... Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
株価
$0.94180721
時価総額
$22.26M
変化(1日)
0.38%
変化(1年)
-14.35%
FR
取引 Valbiotis SA (ALVAL)

カテゴリー

Valbiotis SA(ALVAL)の収益
Dec 2025 時点の収益 TTM: $1.06M
Valbiotis SA の最新の財務報告によると、現在の収益 (TTM) は $1.06M です。2023 年には $5.23M の収益があり、これは 2022 年の $842.05K と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Valbiotis SA の収益履歴(2015 ~ 2026)
各年末の収益
収益 変化
2026 (TTM) $1.06M 483.09%
2024 $182.10K -96.52%
2023 $5.23M 521.36%
2022 $842.05K 148.49%
2021 $338.87K -91.00%
2020 $3.77M 3,588.18%
2019 $102.10K 12.47%
2018 $90.78K 2,421.95%
2017 $3.60K -99.47%
2016 $679.71K 6,159.87%
2015 $10.86K 0.00%
同業他社の収益
企業 収益 収益の差
$52.05B 4,901,516.93%
DK
$12.26B 1,154,073.15%
US
$14.92B 1,405,013.12%
US
$9.08B 855,259.12%
BE
$4.94B 465,536.55%
NL